Article By:
Terry Chrisomalis
Wednesday, July 29, 2020 9:54 AM EDT
Protalix Biotherapeutics (PLX) offers great potential in the coming months as its lead candidate, PLX-102 - a therapy for Fabry disease, is edging closer to the finish line.